Cyclacel Pharmaceuticals Inc (CYCC.OQ) Quote| Reuters.com
Edition:
United States

Cyclacel Pharmaceuticals Inc (CYCC.OQ)

CYCC.OQ on NASDAQ Stock Exchange Capital Market

4.81USD
28 Jun 2016
Change (% chg)

$0.22 (+4.79%)
Prev Close
$4.59
Open
$4.59
Day's High
$5.06
Day's Low
$4.59
Volume
1,794
Avg. Vol
10,049
52-wk High
$12.60
52-wk Low
$3.60

CYCC.OQ

Chart for CYCC.OQ

About

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor... (more)
No analyst recommendations are available for CYCC.OQ.

Overall

Beta: 3.49
Market Cap(Mil.): $13.80
Shares Outstanding(Mil.): 3.01
Dividend: --
Yield (%): --

Financials

  CYCC.OQ Industry Sector
P/E (TTM): -- 38.36 34.67
EPS (TTM): -4.98 -- --
ROI: -57.62 -6.77 14.11
ROE: -59.04 -6.10 15.33

BRIEF-Cyclacel Pharmaceuticals may issue, sell shares having aggregate offering price of up to $4 mln through FBR

* Sales agreement with FBR Capital Markets & Co; may issue, sell shares having aggregate offering price of up to $4 million through FBR Source text: http://1.usa.gov/28Qcw2y Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 23 2016

BRIEF-Cyclacel Pharmaceuticals files for mixed shelf of up to $100 mln - SEC filing

* Files for mixed shelf of up to $100 million - sec filing Source: (http://1.usa.gov/1WIQTTw ) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 10 2016

BRIEF-Cyclacel Pharmaceuticals announces reverse stock split

* Cyclacel announces reverse stock split Source text for Eikon: Further company coverage: (Bengaluru Newsroom +1-646-223-8780)

May 27 2016

BRIEF-Cyclacel Pharmaceuticals files for mixed shelf of up to $53.6 mln - SEC Filing

* Files for mixed shelf of up to $53.6 million - sec filing Source text (http://1.usa.gov/1pQ9azJ) Further company coverage: (Bengaluru Newsroom; +1 646 223 8780; )

Apr 29 2016

BRIEF-Cyclacel Pharmaceuticals reports Q4 revenue of $400,000

* Estimates it has capital resources to reach beyond final analysis of seamless and continue existing programs through end of 2017

Mar 24 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$92.00
Provider : Pechala's Reports
$25.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.